Randomized, Sham-Controlled Investigation of the Leia Sensory Prosthesis in Individuals With Peripheral Neuropathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMYNERVA AG

About this trial

This study will evaluate a wearable device intended to support balance and gait in adults with peripheral neuropathy. Participants will use the device for a defined period, and outcomes related to safety, usability, and functional performance will be assessed.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed informed consent prior to any study procedure

Adults ≥ 18 years

Clinical diagnosis of peripheral neuropathy, confirmed per site procedures and neurophysiological testing (e.g. NCV)

Gait or balance difficulties as self-reported and confirmed by Functional Gait Assessment (FGA score ≤ 23) and/or single-leg stance < 30 seconds

Disqualifiers

Untreated/unhealed lesion of any kind (e.g., wounds, swelling, infection, inflamed area of skin or eruptions on the lower leg (foot and ankle) or near product use (e.g., untreated lymphedema, phlebitis, thrombo-phlebitis or varicose veins)

Untreated/unhealed fractures in the foot and ankle

Cancerous growth in the planned treatment area

Severe peripheral vascular disease (e.g., gangrene)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Active wearable device

    Device

    A non-invasive wearable device used to assess balance, gait, and usability in individuals with peripheral neuropathy.

  • Sham wearable device

    Device

    A sham version of the wearable device without active functionality.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Active DeviceExperimental treatment 1 intervention
Group B: Sham DeviceSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Functional Gait Assessment (FGA) total score

The FGA is a validated clinical scale that assesses gait function and balance under various walking tasks.

Time frame
Change in Functional Gait Assessment (FGA) total score from baseline (day 0) to day 56.

Secondary outcomes

1

Functional Gait Assessment (FGA) total score

The FGA is a validated clinical scale that assesses gait function and balance under various walking tasks. To gain additional knowledge on whether there are changes between supervised and home-use phase

Time frame
From baseline (day 0) to the end of the supervised period (day 28), change from day 28 to day 56, and evaluation of evolution across all timepoints, with and without stimulation
2

Timed-up and Go (TUG) in seconds

The Timed Up and Go (TUG) test assesses functional mobility. Participants are instructed to stand up from a chair, walk 3 metres at their usual pace, turn around, walk back to the chair, and sit down. The time from the command to start until the participant is seated again is recorded in seconds. A shorter time indicates better functional mobility.

Time frame
Change from Baseline to day 56
3

Neuropathic pain symptoms (NPSI questionnaire)

Captures changes in neuropathic pain intensity and quality.

Time frame
Change from baseline to each of the follow-up time points (day 7, 14, 28, 35, 42, 49, 56 and 80)
4

Quality of life (NORFOLK QOL-DN, EQ-5D-5L questionnaire)

Evaluates impact of intervention on daily function and well-being.

Time frame
Change from baseline to day 28, day 56 and day 80

Other outcomes

1

Exploratory - Sensory function - Temperature measurement using the thermal imaging camera

Temperature distribution in the feet)

Time frame
Change from baseline value from day 7 prestimulation to follow-up time points day 28 and 56
2

Safety Outcome

All Adverse events (AEs): incidence, severity, seriousness, relatedness to device/procedures

Time frame
through study completion, an average of 4 months
3

Safety Outcome

All Device deficiencies: number, type, corrective actions

Time frame
through study completion, an average of 4 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.